Production (Stage)
OnKure Therapeutics, Inc.
OKUR
$2.88
$0.020.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 215.26% | 285.47% | 220.63% | 2.93% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 72.92% | 80.47% | 66.12% | 12.33% | |
| Operating Income | -72.92% | -80.47% | -66.12% | -12.33% | |
| Income Before Tax | -67.00% | -84.47% | -72.79% | -9.87% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -67.00% | -84.47% | -72.79% | -9.87% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -67.00% | -84.47% | -72.79% | -9.87% | |
| EBIT | -72.92% | -80.47% | -66.12% | -12.33% | |
| EBITDA | -73.74% | -81.37% | -66.74% | -12.28% | |
| EPS Basic | 96.09% | -92.64% | -71.42% | -2,804.07% | |
| Normalized Basic EPS | 96.09% | -82.01% | -71.44% | -2,804.35% | |
| EPS Diluted | 96.09% | -92.64% | -71.42% | -2,804.07% | |
| Normalized Diluted EPS | 96.09% | -82.01% | -71.44% | -2,804.35% | |
| Average Basic Shares Outstanding | 4,175.25% | -4.23% | 0.79% | -96.22% | |
| Average Diluted Shares Outstanding | 4,175.25% | -4.23% | 0.79% | -96.22% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |